Screening Tests of Reproductive Immunology in Systemic Lupus Erythematosus

Table 1

Prevalence of positive results for each performed antibody analysis with comparison between study and control groups.

Antibody	Number of positive subjects		Odds ratio (95% confidence interval)
	Study group (𝑛=52)	Control group (𝑛=25)
Antisperm antibodies (ASAs)
Serum ASA	5/52 (9.6%)	1/25 (4.0%)	2.55 (0.28–23.10)
Cervical ovulatory mucus ASA	6/52 (11.5%)	1/25 (4.0%)	3.13 (0.36–27.52)
Antizona pellucida antibodies (aZP)
aZP IgG	12/52 (23.0%)	0/25 (0.0%)	N/A
aZP IgM	1/52 (1.9%)	0/25 (0.0%)	N/A
Antiphospholipid antibodies (aPL) against
phosphatic acid IgG	1/52 (1.9%)	0/25 (0.0%)	N/A
phosphatic acid IgM	0/52 (0.0%)	0/25 (0.0%)	N/A
phosphatidyl glycerol IgG	2/52 (3.8%)	0/25 (0.0%)	N/A
phosphatidyl glycerol IgM	0/52 (0.0%)	0/25 (0.0%)	N/A
phosphatidyl inositol IgG	35/52 (67.3%)	0/25 (0.0%)	N/A
phosphatidyl inositol IgM	2/52 (3.8%)	1/25 (4.0%)	0.96 (0.08–11.12)
phosphatidyl ethanolamine IgG	16/52 (30.8%)	0/25 (0.0%)	N/A
phosphatidyl ethanolamine IgM	3/52 (5.8%)	1/25 (4.0%)	1.47 (0.15–14.88)
phosphatidyl serine IgG	32/52 (61.5%)	0/25 (0.0%)	N/A
phosphatidyl serine IgM	2/52 (3.8%)	2/25 (8.0%)	0.46 (0.06–3.47)
cardiolipin IgG	16/52 (30.8%)	2/25 (8.0%)	5.11 (1.07–24.33)
cardiolipin IgM	4/52 (7.7%)	0/25 (0.0%)	N/A
beta-2-glycoprotein IgG	15/52 (28.8%)	0/25 (0.0%)	N/A
beta-2-glycoprotein IgA	9/52 (17.3%)	0/25 (0.0%)	N/A
annexin-V	7/52 (13.5%)	0/25 (0.0%)	N/A

Note: statistically significant values are marked in bold script.